1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Short Bowel Syndrome (SBS) Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Short Bowel Syndrome (SBS) Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Glucagon-Like Peptide-2 (GLP-2)
1.4.3 Growth Hormone
1.4.4 Glutamine
1.4.5 Other
1.5 Market by Application
1.5.1 Global Short Bowel Syndrome (SBS) Drugs Market Share by Application: 2021-2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Retail Pharmacies
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Short Bowel Syndrome (SBS) Drugs Market
1.8.1 Global Short Bowel Syndrome (SBS) Drugs Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Short Bowel Syndrome (SBS) Drugs Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Short Bowel Syndrome (SBS) Drugs Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Short Bowel Syndrome (SBS) Drugs Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Short Bowel Syndrome (SBS) Drugs Sales Volume Market Share by Region (2015-2020)
3.2 Global Short Bowel Syndrome (SBS) Drugs Sales Revenue Market Share by Region (2015-2020)
3.3 North America Short Bowel Syndrome (SBS) Drugs Sales Volume
3.3.1 North America Short Bowel Syndrome (SBS) Drugs Sales Volume Growth Rate (2015-2020)
3.3.2 North America Short Bowel Syndrome (SBS) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Short Bowel Syndrome (SBS) Drugs Sales Volume
3.4.1 East Asia Short Bowel Syndrome (SBS) Drugs Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Short Bowel Syndrome (SBS) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Short Bowel Syndrome (SBS) Drugs Sales Volume (2015-2020)
3.5.1 Europe Short Bowel Syndrome (SBS) Drugs Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Short Bowel Syndrome (SBS) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Short Bowel Syndrome (SBS) Drugs Sales Volume (2015-2020)
3.6.1 South Asia Short Bowel Syndrome (SBS) Drugs Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Short Bowel Syndrome (SBS) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Short Bowel Syndrome (SBS) Drugs Sales Volume (2015-2020)
3.7.1 Southeast Asia Short Bowel Syndrome (SBS) Drugs Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Short Bowel Syndrome (SBS) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Short Bowel Syndrome (SBS) Drugs Sales Volume (2015-2020)
3.8.1 Middle East Short Bowel Syndrome (SBS) Drugs Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Short Bowel Syndrome (SBS) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Short Bowel Syndrome (SBS) Drugs Sales Volume (2015-2020)
3.9.1 Africa Short Bowel Syndrome (SBS) Drugs Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Short Bowel Syndrome (SBS) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Short Bowel Syndrome (SBS) Drugs Sales Volume (2015-2020)
3.10.1 Oceania Short Bowel Syndrome (SBS) Drugs Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Short Bowel Syndrome (SBS) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Short Bowel Syndrome (SBS) Drugs Sales Volume (2015-2020)
3.11.1 South America Short Bowel Syndrome (SBS) Drugs Sales Volume Growth Rate (2015-2020)
3.11.2 South America Short Bowel Syndrome (SBS) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Short Bowel Syndrome (SBS) Drugs Sales Volume (2015-2020)
3.12.1 Rest of the World Short Bowel Syndrome (SBS) Drugs Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Short Bowel Syndrome (SBS) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Short Bowel Syndrome (SBS) Drugs Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Short Bowel Syndrome (SBS) Drugs Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Short Bowel Syndrome (SBS) Drugs Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Short Bowel Syndrome (SBS) Drugs Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Short Bowel Syndrome (SBS) Drugs Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Short Bowel Syndrome (SBS) Drugs Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Short Bowel Syndrome (SBS) Drugs Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Short Bowel Syndrome (SBS) Drugs Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Short Bowel Syndrome (SBS) Drugs Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Short Bowel Syndrome (SBS) Drugs Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Short Bowel Syndrome (SBS) Drugs Sales Volume Market Share by Type (2015-2020)
14.2 Global Short Bowel Syndrome (SBS) Drugs Sales Revenue Market Share by Type (2015-2020)
14.3 Global Short Bowel Syndrome (SBS) Drugs Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Short Bowel Syndrome (SBS) Drugs Consumption Volume by Application (2015-2020)
15.2 Global Short Bowel Syndrome (SBS) Drugs Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Short Bowel Syndrome (SBS) Drugs Business
16.1 Merck
16.1.1 Merck Company Profile
16.1.2 Merck Short Bowel Syndrome (SBS) Drugs Product Specification
16.1.3 Merck Short Bowel Syndrome (SBS) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Sancilio Pharmaceuticals
16.2.1 Sancilio Pharmaceuticals Company Profile
16.2.2 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Specification
16.2.3 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Ardelyx
16.3.1 Ardelyx Company Profile
16.3.2 Ardelyx Short Bowel Syndrome (SBS) Drugs Product Specification
16.3.3 Ardelyx Short Bowel Syndrome (SBS) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Takeda
16.4.1 Takeda Company Profile
16.4.2 Takeda Short Bowel Syndrome (SBS) Drugs Product Specification
16.4.3 Takeda Short Bowel Syndrome (SBS) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 OxThera
16.5.1 OxThera Company Profile
16.5.2 OxThera Short Bowel Syndrome (SBS) Drugs Product Specification
16.5.3 OxThera Short Bowel Syndrome (SBS) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Emmaus Medical
16.6.1 Emmaus Medical Company Profile
16.6.2 Emmaus Medical Short Bowel Syndrome (SBS) Drugs Product Specification
16.6.3 Emmaus Medical Short Bowel Syndrome (SBS) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Nutrinia
16.7.1 Nutrinia Company Profile
16.7.2 Nutrinia Short Bowel Syndrome (SBS) Drugs Product Specification
16.7.3 Nutrinia Short Bowel Syndrome (SBS) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Naia Pharmaceuticals
16.8.1 Naia Pharmaceuticals Company Profile
16.8.2 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Specification
16.8.3 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Zealand Pharma
16.9.1 Zealand Pharma Company Profile
16.9.2 Zealand Pharma Short Bowel Syndrome (SBS) Drugs Product Specification
16.9.3 Zealand Pharma Short Bowel Syndrome (SBS) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Short Bowel Syndrome (SBS) Drugs Manufacturing Cost Analysis
17.1 Short Bowel Syndrome (SBS) Drugs Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Short Bowel Syndrome (SBS) Drugs
17.4 Short Bowel Syndrome (SBS) Drugs Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Short Bowel Syndrome (SBS) Drugs Distributors List
18.3 Short Bowel Syndrome (SBS) Drugs Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Short Bowel Syndrome (SBS) Drugs (2021-2026)
20.2 Global Forecasted Revenue of Short Bowel Syndrome (SBS) Drugs (2021-2026)
20.3 Global Forecasted Price of Short Bowel Syndrome (SBS) Drugs (2015-2026)
20.4 Global Forecasted Production of Short Bowel Syndrome (SBS) Drugs by Region (2021-2026)
20.4.1 North America Short Bowel Syndrome (SBS) Drugs Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Short Bowel Syndrome (SBS) Drugs Production, Revenue Forecast (2021-2026)
20.4.3 Europe Short Bowel Syndrome (SBS) Drugs Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Short Bowel Syndrome (SBS) Drugs Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Short Bowel Syndrome (SBS) Drugs Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Short Bowel Syndrome (SBS) Drugs Production, Revenue Forecast (2021-2026)
20.4.7 Africa Short Bowel Syndrome (SBS) Drugs Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Short Bowel Syndrome (SBS) Drugs Production, Revenue Forecast (2021-2026)
20.4.9 South America Short Bowel Syndrome (SBS) Drugs Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Short Bowel Syndrome (SBS) Drugs Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Short Bowel Syndrome (SBS) Drugs by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Short Bowel Syndrome (SBS) Drugs by Country
21.2 East Asia Market Forecasted Consumption of Short Bowel Syndrome (SBS) Drugs by Country
21.3 Europe Market Forecasted Consumption of Short Bowel Syndrome (SBS) Drugs by Countriy
21.4 South Asia Forecasted Consumption of Short Bowel Syndrome (SBS) Drugs by Country
21.5 Southeast Asia Forecasted Consumption of Short Bowel Syndrome (SBS) Drugs by Country
21.6 Middle East Forecasted Consumption of Short Bowel Syndrome (SBS) Drugs by Country
21.7 Africa Forecasted Consumption of Short Bowel Syndrome (SBS) Drugs by Country
21.8 Oceania Forecasted Consumption of Short Bowel Syndrome (SBS) Drugs by Country
21.9 South America Forecasted Consumption of Short Bowel Syndrome (SBS) Drugs by Country
21.10 Rest of the world Forecasted Consumption of Short Bowel Syndrome (SBS) Drugs by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer